Romiplostim as a treatment for immune thrombocytopenia: A review

Journal of Blood Medicine

Volumn 6, Issue , 2015, Pages 37-44

  Chalmers, Sarah ^a,b   Tarantino, Michael D ^a,b,c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b The Children s Hospital of illinois   (United States)

^c Bleeding and Clotting Disorders Institute   (United States)

Author keywords

Megakaryocyte; Peptibody; Thrombopoietin; Thrombopoietin receptor agonist

Indexed keywords

AUTOANTIBODY; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN;

AUTOIMMUNE THROMBOCYTOPENIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FIBROSIS; IMMUNOBLAST; IMMUNOLOGICAL TOLERANCE; MEGAKARYOCYTE; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS;

EID: 84939121037     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S47240     Document Type: Review

References (85)

1. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010;85(3): 174-180.
2. Imbach P, Akatsuka J, Blanchette VS, et al. Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr. 1995;154(9 Suppl 4):S60-S64.
3. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909-913.
4. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR; Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122(6): 966-974.
5. Burt S. Purpura hemorrhagiva, or morhus maculosus of Werlhof. N Engl J Med. 1900;143:441-444.
6. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38(1):1-10.
7. Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965;124(2):499-542.
8. Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Evidence for a light chain restriction of glycoprotein Ib/IX and IIb/IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP). Br J Haematol. 1995;90(1):175-179.
9. He R, Reid DM, Jones CE, Shulman NR. Extracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpura. Blood. 1995;86(10):3789-3796.
10. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood. 1982;59(1):23-26.
11. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1981;80(1): 33-40.
12. McMillan R, Luiken GA, Levy R, Yelenosky R, Longmire RL. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. J Am Med Assoc. 239(23):2460-2462.
13. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994;83(4):1024-1032.
14. Tarantino MD, Goldsmith G. Treatment of acute immune thrombocytopenic purpura. Semin Hematol. 1998;35(1 Suppl 1):28-35.
15. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
16. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
17. Godeau B, Chevret S, Varet B, et al; French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23-29.
18. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123(6):989-995.
19. Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147(4):521-527.
20. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-5995.
21. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107(7):2639-2642.
22. Mueller BU, Bennett CM, Feldman HA, et al; Pediatric Rituximab/ITP Study Group; Glaser Pediatric Research Network. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer. 2009;52(2): 259-262.
23. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146(2):217-221.
24. Parodi E, Rivetti E, Amendola G, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol. 2009;144(4):552-558.
25. Reiner A, Gersheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351-358.
26. Schiavotto C, Castamann G, Rodeghiero F. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Haematologica. 1993;78(6 Suppl 2):29-34.
27. Facon T, Caulier MT, Wattel E, Jouet JP, Bauters F, Fenaux P. A randomized trial comparing vinblastine in slow infusion and by bolus iv injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol. 1994;86(3):678-680.
28. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood. 1984;64(6):1179-1183.
29. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328(17):1226-1229.
30. Weinblatt ME, Kochen J, Ortega J. Danazol for children with immune thrombocytopenic purpura. Am J Dis Child. 1988;142(12):1317-1319.
31. Marwaha RK, Singh RP, Garewal G, Marwaha N, Prakash D, Sarode R. Colchicine therapy in immune thrombocytopenic purpura. Acta Paediatr Scand. 1990;79(11):1118-1120.
32. Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Arch Intern Med. 1984;144(11):2198-2200.
33. Ishii H, Oh H, Uchida Y, et al. Effect of interferon (IFN) on refractory idiopathic thrombocytopenic purpura: administration of 6 million units of recombinant IFN alpha-2b. Intern Med. 1992;31(12):1343-1347.
34. Brox AG, Howson-Jan K, Fauser AA. Treatment of idiopathic thrombocytopenic purpura with ascorbate. Br J Haematol. 1988;70(3):341-344.
35. Kuter D. Milestones in understanding platelet production: a historical overview. Br J Haematol. 2014;165(2):248-258.
36. Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369(6481):571-574.
37. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369(6481):568-571.
38. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533-538.
39. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91(23):11104-11108.
40. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348(9037):1279-1281.
41. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132(5):364-368.
42. Komatsu N, Okamoto T, Yoshida T. Pegylated recombinant human megakaryocyte growth and development factor increased platelet count in patients with aplastic anemia and myelodysplastic syndrome. Blood. 2000;96:296a.
43. Rice L, Nichol JL, McMillan R, Roskos LK, Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol. 2001;68(3):210-214.
44. Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood. 2001;98(5):1346-1351.
45. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98(5):1339-1345.
46. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002;359(9324):2145-2152.
47. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241-3248.
48. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276(5319):1696-1699.
49. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25(2):52-60.
50. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
51. US Food and Drug Administration (FDA). FDA drug safety communication: modified risk evaluation and mitigation strategies (REMS) for Nplate (romiplostim) and Promacta (eltrombopag) [web page on the Internet]. Rockville, MD: FDA; December 6, 2011 [updated December 15, 2011]. Available from: http://www.fda.gov/drugs/drugsafety/ucm280165/htm. Accessed August 8, 2014.
52. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16): 1672-1681.
53. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889-1899.
54. Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411-423.
55. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011; 118(16):4338-4345.
56. George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409-415.
57. Michel M, te Boekhorst PA, Janssens A, et al. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology. 2011;16(5):274-277.
58. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013;53(11):2807-2812.
59. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev. 2011;(7):CD008235.
60. Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8(6):1372-1382.
61. Saleh MN, Bussel JB, Cheng G, et al; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537-545.
62. Mahévas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165(6):865-869.
63. Leven E, Hsieh L, Ramaswamy K, McGuinn CE, Nugent D, Bussel JB. Safe and effective use of romiplostim and eltrombopag in children with ITP. ASH Annual Meeting Abstracts. 2013;311: Abstract 3541.
64. Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol. 2011;155(2):248-255.
65. Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol. 2012;25(1):65-74.
66. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161-2171.
67. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009; 114(18):3748-3756.
68. Ettrup MS, Jensen AØ, Engebjerg MC, et al. Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nationwide study. Am J Hematol. 2010;85(12):930-934.
69. Beckman EN, Brown AW Jr. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med. 1990;114(12):1241-1243.
70. Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol. 1971;56(1):24-31.
71. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10-23.
72. Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838-1846.
73. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28-36.
74. Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol. 2011;90(11):1341-1344.
75. Tarantino MD, Bussel JB, Geddis A, et al. Safety and efficacy of long-term open-label romiplostim dosing in thrombocytopenic pediatric patients with immune thrombocytopenia (ITP). Blood. 2013; 122(21):3530.
76. Pasquet M, Aladjidi N, Guiton C, et al; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE). Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol. 2014;164(2):266-271.
77. Amgen. Safety and efficacy study of romiplostim (AMG 531) to treat ITP in pediatric subjects. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2007 [updated July 18, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00515203. NLM identifier: NCT00515203. Accessed August 24, 2014.
78. MD Anderson Cancer Center. AMG 531 in patients with advanced malignancy receiving treatment with carboplatin. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2005 [updated April 7, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00147225. NLM identifier: NCT00147225. Accessed August 24, 2014.
79. MD Anderson Cancer Center. Study of AMG 531 to evaluate the safety and efficacy in patients with non-Hodgkin's lymphoma. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2006 [updated September 4, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00299182. NLM identifier: NCT00299182. Accessed August 24, 2014.
80. Memorial Sloan-Kettering Cancer Center. Study of romiplostim versus observation for chemotherapy induced thrombocytopenia. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2014 [updated August 14, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02052882?term=soff+romiplostim&rank=1. NLM identifier: NCT02052882. Accessed October 12, 2014.
81. New York University School of Medicine. Romiplostim in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated September 12, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01676961. NLM identifier: NCT01676961. Accessed August 24, 2014.
82. Amgen. Dose/Schedule finding trial of romiplostim for chemotherapy-induced thrombocytopenia (CIT) in non-small cell lung cancer (NSCLC). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2006 [updated September 18, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00413283. NLM identifier: NCT00413283. Accessed August 24, 2014.
83. Amgen. Nplate® pregnancy exposure registry (NPER). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2014 [updated June 24, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02090088. NLM identifier: NCT02090088. Accessed August 24, 2014.
84. Kyowa Hakko Kirin Korea Co, Ltd. A phase 2 study to evaluate the efficacy and safety of AMG531 in aplastic anemia. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2014 [updated March 20, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02094417. NLM identifier: NCT02094417. Accessed August 24, 2014.
85. University of Southern California. Romiplostim in treating hepatitis c-infected patients with thrombocytopenia. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated July 22, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01153919. NLM identifier: NCT01153919. Accessed August 24, 2014.